Interest in daily clinical practice of screening for gouty disease in patients with psoriatic arthritis

Abstract Objectives PsA and gout are two prevalent rheumatic diseases, that can be associated as part of a rheumatism known as ‘Psout’. Both conditions are associated with cardiovascular (CV) risk, thus their co-occurrence could have significant implications for the management of CV risks and patient care. This study aimed to determine the prevalence of gout within a PsA patient cohort and, consequently, to identify factors associated with this pathological association. Methods This is an observational, descriptive, cross-sectional, single-center study, including patients diagnosed with PsA. Demographic, clinical, biological and imaging data were collected. We identified the proportion of patients simultaneously affected by PsA and gout and compared characteristics between those with and without gout. Results The prevalence of gout among PSA patients was 9.8% (12/122), with a prevalence of 23% for asymptomatic hyperuricemia and 7.4% presenting with specific US signs of gout. Significant associated factors in the univariate analysis included weight, hypertension, diabetes, certain medications (diuretics, aspirin, lipid-lowering agents), impaired renal function, elevated fasting blood glucose, lipid abnormalities and specific US signs of gout. Conclusion Our study has described the existence of patients simultaneously affected by PsA and gout (‘Psout’). Performing joint US along with uric acid level measurements in PsA patients can enable personalized therapeutic care. Lay Summary What does this mean for patients? Psoriatic arthritis (PsA) and gout are two common rheumatic diseases that can coexist in the same individual. Not recognizing this association can pose a challenge in the usual therapeutic management of patients. For people with PsA, identifying gout can lead to better management of their rheumatism, particularly in the selection of treatment, permitting an appropriate care approach for both diseases. Furthermore, both PsA and gout are known to increase the risk of heart problems and, consequently, the likelihood of death. Highlighting this association and the higher risk of heart problems in affected patients serves as a reminder for healthcare practitioners. Indeed, the overall management of people with PsA involves conducting a comprehensive cardiovascular assessment and managing the prevention of heart problems, especially in the risk of associated gout.